Compare GSK plc (GSK) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Tyson Foods, Inc. — how do they compare? GSK plc trades at $52.6 (market cap $101.34B), while Tyson Foods, Inc. trades at $57.97 (market cap $20.24B). The key difference: GSK plc is far larger — about 5× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays the higher dividend (3.55%). Which is the better fit depends on your goals.
| GSK | TSN | |
|---|---|---|
Market Cap | $101.34B | $20.24B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $68.75 |
52-Week Low | $36.20 | $50.72 |
Enterprise Value | $121.95B | $27.82B |
Dividend Yield | 3.49% | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Tyson Foods (TSN) trades at $57.97, up 0.84% today, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025. Revenue grew to $54.44 billion in 2025, though net margins remain thin at 0.81%. Recent news highlights innovation in prepared foods and new executive leadership.
The stock offers a consensus price target of $68.80, implying 19% upside, supported by 50% analyst buy ratings. Risks include volatile earnings, high debt, and competitive pressures. Long-term growth in prepared foods and dividend payments provide stability, but near-term performance depends on execution amid economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
